Pfizer, U.S. ink $5.29B deal for possible COVID-19 treatment

The U.S. government will pay drugmaker Pfizer $5.29 billion for 10 million treatment courses of its potential COVID-19 treatment if regulators approve it

NEW YORK — The U.S. government will pay drugmaker Pfizer $5.29 billion for 10 million treatment courses of its potential COVID-19 treatment if regulators approve it.

The FDA is already reviewing a competing pill from Merck and will hold a public meeting on it later this month.

The price for Pfizer’s potential treatment amounts to about $529 per course. The U.S. has already agreed to pay roughly $700 per course of Merck’s drug for about 1.7 million treatments.

Pfizer said Thursday the price being paid by the U.S. government reflects the high number of treatment courses purchased through 2022.

Be the first to comment

Leave a Reply

Your email address will not be published.


*